General
Preferred name
EFLORNITHINE
Synonyms
Alpha-Difluoromethylornithine ()
EFLORNITHINE HYDROCHLORIDE HYDRATE ()
2,5-Diamino-2-(difluoromethyl)pentanoic acid, monohydrochloride, monohydrate ()
DL-alpha-Difluoromethylornithine hydrochloride ()
MDL71782 hydrochloride ()
Eflornithine (hydrochloride) ()
¦Á-difluoromethylornithine hydrochloride hydrate ()
DFMO hydrochloride ()
RMI71782 hydrochloride ()
¦Á-difluoromethylornithine hydrochloride ()
¦Á-difluoromethylornithine ()
MDL-71782 hydrochloride hydrate ()
RMI-71782 hydrochloride hydrate ()
??-difluoromethylornithine hydrochloride hydrate ()
DFMO hydrochloride hydrate ()
EFLORNITHINE HYDROCHLORIDE ()
Difluoromethylornithine hydrochloride hydrate ()
Eflornithine hydrochloride Monohydrate ()
DFMO ()
??-difluoromethylornithine hydrochloride ()
??-difluoromethylornithine ()
Ornidyl ()
Eflornithine (hydrochloride hydrate) ()
L-EFLORNITHINE HYDROCHLORIDE ()
MDL71782 ()
RMI71782 ()
α-difluoromethylornithine ()
α-difluoromethylornithine hydrochloride hydrate ()
Eflornithine (MDL-71782) hydrochloride hydrate ()
Difluoromethylornithine hydrochloride hydrate, DFMO hydrochloride hydrate, RMI-71782 hydrochloride hydrate, ¦Á-difluoromethylornithine hydrochloride hydrate ()
MDL-71782-A ()
Vaniqa ()
RMI-71782-A ()
NSC-270295 ()
NSC-337250 ()
Eflornithine HCl ()
MDL-71782A ()
Dfmo Hcl ()
Eflornithine hydrochloride monohydrate ()
Difluromethylornithine ()
MDL 71,782 A ()
DL-alpha-Difluoromethylornithine HCl ()
Eflornithine Hydrocloride ()
DL-.alpha.-Difluoromethylornithine (hydrochloride hydrate)? ()
P&D ID
PD009312
CAS
68278-23-9
67037-37-0
70052-12-9
96020-91-6
Tags
drug candidate
natural product
drug
available
Approved by
FDA
First approval
1990
Drug Status
investigational
approved
withdrawn
Drug indication
Antineoplastic
African trypanosomiasis
Trypanosomiasis
Antiprotozoal
Max Phase
Phase 2
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
METABOLISM
Not metabolized;
DESCRIPTION
Eflornithine is an irreversible ornithine decarboxylase inhibitor and is a partial inhibitor of arginase enzymes . Marketed formulations may contain eflornithine hydrochloride (PubChem CID 57004).
Eflornithine has recently been reported to provide neuroprotective effects in a mouse model of Alzheimer's disease (AD) . The authors identify microglial-induced arginine depletion as a causative factor in AD pathophysiology in their model, focussing on inhibition of arginine catabolising enzymes as a novel mechanism by which to halt the neurodegeneration observed in AD. These findings suggest that eflornithine could be used as a starting point for medicinal chemists to identify novel compounds with anti-arginase activity in humans. (GtoPdb)
Eflornithine has recently been reported to provide neuroprotective effects in a mouse model of Alzheimer's disease (AD) . The authors identify microglial-induced arginine depletion as a causative factor in AD pathophysiology in their model, focussing on inhibition of arginine catabolising enzymes as a novel mechanism by which to halt the neurodegeneration observed in AD. These findings suggest that eflornithine could be used as a starting point for medicinal chemists to identify novel compounds with anti-arginase activity in humans. (GtoPdb)
DESCRIPTION
Selective irreversible ornithine decarboxylase (ODC) inhibitor.
(LOPAC library)
DESCRIPTION
Eflornithine hydrochloride is a drug found to be effective in the treatment of facial hirsutism. It is a "suicide inhibitor," irreversibly binding to Ornithine Decarboxylase (ODC) and preventing the natural substrate ornithine from accessing the active site.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
IGF1R inhibitor
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
4
Compound Sets
32
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
Mcule NIBR MoA Box Subset
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Pathogen Box
The Spectrum Collection
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
71
Molecular Weight
182.09
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
0
Aromatic Ring Count
0
cLogP
-0.23
TPSA
89.34
Fraction CSP3
0.83
Chiral centers
1.0
Largest ring
0.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
ODC
Disease
REFERENCE COMPOUNDS
MOA
protozoal ornithine decarboxylase inhibitor
ornithine decarboxylase inhibitor
Inhibitor
Ornithine Decarboxylase Inhibitors
Target
Ornithine decarboxylase
Decarboxylase
ARG2, ODC1
Parasite
Pathway
Metabolism
Anti-infection
Primary Target
Decarboxylases
Member status
member
Indication
facial hair reduction
Biosynthetic Origin
Other (Amino Acid)
Therapeutic Indication
Antiparasitic
Therapeutic Class
Antimicrobial
Anticancer Agents
Source data
